These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 19072665)

  • 1. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
    Goldberg L; Haklai R; Bauer V; Heiss A; Kloog Y
    J Med Chem; 2009 Jan; 52(1):197-205. PubMed ID: 19072665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
    Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
    Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid exerts long-lasting neuroprotection in a mouse closed head injury model.
    Shohami E; Yatsiv I; Alexandrovich A; Haklai R; Elad-Sfadia G; Grossman R; Biegon A; Kloog Y
    J Cereb Blood Flow Metab; 2003 Jun; 23(6):728-38. PubMed ID: 12796721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
    Ling Y; Ye X; Zhang Z; Zhang Y; Lai Y; Ji H; Peng S; Tian J
    J Med Chem; 2011 May; 54(9):3251-9. PubMed ID: 21504204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
    Rotblat B; Ehrlich M; Haklai R; Kloog Y
    Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats.
    da Silva Morais A; Saliez A; Leclercq I; Horsmans Y; Stärkel P
    Clin Sci (Lond); 2008 Jan; 114(1):73-83. PubMed ID: 17678500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice.
    Mor A; Kloog Y; Keren G; George J
    Eur J Pharmacol; 2009 Aug; 616(1-3):301-5. PubMed ID: 19527709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.
    Tsimberidou AM; Rudek MA; Hong D; Ng CS; Blair J; Goldsweig H; Kurzrock R
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):235-41. PubMed ID: 19484470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ras chaperones: new targets for cancer and immunotherapy.
    Kloog Y; Elad-Sfadia G; Haklai R; Mor A
    Enzymes; 2013; 33 Pt A():267-89. PubMed ID: 25033809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
    Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
    Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
    Haklai R; Elad-Sfadia G; Egozi Y; Kloog Y
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):89-96. PubMed ID: 17909812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats.
    Schneider-Merck T; Borbath I; Charette N; De Saeger C; Abarca J; Leclercq I; Horsmans Y; Stärkel P
    Eur J Cancer; 2009 Jul; 45(11):2050-60. PubMed ID: 19427195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of novel farnesylthiosalicylic acid derivatives for cancer treatment.
    Ling Y; Wang X; Zhu H; Wang Z; Xu C; Wang X; Chen L; Zhang W
    Arch Pharm (Weinheim); 2014 May; 347(5):327-33. PubMed ID: 24435839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
    Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
    J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death.
    Blum R; Jacob-Hirsch J; Amariglio N; Rechavi G; Kloog Y
    Cancer Res; 2005 Feb; 65(3):999-1006. PubMed ID: 15705901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice.
    Aizman E; Mor A; Chapman J; Assaf Y; Kloog Y
    J Neuroimmunol; 2010 Dec; 229(1-2):192-203. PubMed ID: 20869125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
    Laheru D; Shah P; Rajeshkumar NV; McAllister F; Taylor G; Goldsweig H; Le DT; Donehower R; Jimeno A; Linden S; Zhao M; Song D; Rudek MA; Hidalgo M
    Invest New Drugs; 2012 Dec; 30(6):2391-9. PubMed ID: 22547163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
    Gana-Weisz M; Halaschek-Wiener J; Jansen B; Elad G; Haklai R; Kloog Y
    Clin Cancer Res; 2002 Feb; 8(2):555-65. PubMed ID: 11839677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice.
    Weisz B; Giehl K; Gana-Weisz M; Egozi Y; Ben-Baruch G; Marciano D; Gierschik P; Kloog Y
    Oncogene; 1999 Apr; 18(16):2579-88. PubMed ID: 10353601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.